Paclitaxel resistance by random mutagenesis of α-tubulin

Cytoskeleton

Volumn 70, Issue 12, 2013, Pages 849-862

  Yin, Shanghua ^a   Zeng, Changqing ^a,b   Hari, Malathi ^a,c   Cabral, Fernando ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b Chinese Academy of Sciences and China National Center for Bioinformation   (China)

^c UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Cancer; Drug resistance; Microtubules; Mitosis; Multinucleation; Neurological defects; Taxanes; Vinblastine

Indexed keywords

ALPHA TUBULIN; COMPLEMENTARY DNA; GENOMIC DNA; PACLITAXEL;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CANCER RESISTANCE; CHO CELL; CONTROLLED STUDY; DNA DAMAGE; FEMALE; GENE SEQUENCE; GENETIC TRANSFECTION; GENETIC VARIABILITY; MICROTUBULE ASSEMBLY; MUTAGENESIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SITE DIRECTED MUTAGENESIS;

MAMMALIA;

CANCER; DRUG RESISTANCE; MICROTUBULES; MITOSIS; MULTINUCLEATION; NEUROLOGICAL DEFECTS; TAXANES; VINBLASTINE;

AMINO ACID SEQUENCE; ANIMALS; CHO CELLS; CRICETULUS; DRUG RESISTANCE; HUMANS; MICROTUBULES; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; PACLITAXEL; TRANSFECTION; TUBULIN;

EID: 84890180718     PISSN: 19493584     EISSN: 19493592     Source Type: Journal    
DOI: 10.1002/cm.21154     Document Type: Article

References (57)

1. Abraham I, Marcus M, Cabral F, Gottesman MM. 1983. Mutations in α- and β-tubulin affect spindle formation in Chinese hamster ovary cells. J Cell Biol 97:1055-1061.
2. Bahi-Buisson N, Poirier K, Boddaert N, Saillour Y, Castelnau L, Philip N, Buyse G, Villard L, Joriot S, Marret S, et al. 2008. Refinement of cortical dysgeneses spectrum associated with TUBA1A mutations. J Med Genet 45:647-653.
3. Begaye A, Trostel S, Zhao Z, Taylor RE, Schriemer DC, Sackett DL. 2011. Mutations in the beta-tubulin binding site for peloruside A confer resistance by targeting a cleft significant in side chain binding. Cell Cycle 10:3387-3396.
4. Bhattacharya R, Cabral F. 2004. A ubiquitous β-tubulin disrupts microtubule assembly and inhibits cell proliferation. Mol Biol Cell 15:3123-3131.
5. Boggs B, Cabral F. 1987. Mutations affecting assembly and stability of tubulin: Evidence for a non-essential β-tubulin in CHO cells. Mol Cell Biol 7:2700-2707.
6. Cabral F. 1983. Isolation of Chinese hamster ovary cell mutants requiring the continuous presence of taxol for cell division. J Cell Biol 97:22-29.
7. Cabral F. 2001. Factors determining cellular mechanisms of resistance to antimitotic drugs. Drug Resistance Updates 3:1-6.
8. Cabral F. 2008. Mechanisms of resistance to drugs that interfere with microtubule assembly. In: Fojo AT, editor. Cancer Drug Discovery and Development: The Role of Microtubules in Cell Biology, Neurobiology, and Oncology. Totowa, NJ: Humana Press. pp 337-356.
9. Cabral F, Gottesman MM. 1978. The determination of similarities in amino acid composition among proteins separated by two-dimensional gel electrophoresis. Anal Biochem 91:548-556.
10. Cabral F, Schatz G. 1979. High resoultion one- and two-dimensional electrophoretic analysis of mitochondrial membrane proteins. Methods Enzymol 56:602-613.
11. Cabral F, Sobel ME, Gottesman MM. 1980. CHO mutants resistant to colchicine, colcemid or griseofulvin have an altered β-tubulin. Cell 20:29-36.
12. Cabral F, Wible L, Brenner S, Brinkley BR. 1983. Taxol-requiring mutant of Chinese hamster ovary cells with impaired mitotic spindle assembly. J Cell Biol 97:30-39.
13. Cabral F, Brady RC, Schibler MJ. 1986. A mechanism of cellular resistance to drugs that interfere with microtubule assembly. Ann N Y Acad Sci 466:745-756.
14. DeLano WL. 2005. Macpymol: A Pymol-Based Molecular Graphics Application for Mac OSX. South San Francisco, CA: DeLano Scientific LLC.
15. Dumontet C, Jordan MA. 2010. Microtubule-binding agents: A dynamic field of cancer therapeutics. Nat Rev Drug Discov 9:790-803.
16. Elliott EM, Okayama H, Sarangi F, Henderson G, Ling V. 1985. Differential expression of three α-tubulin genes in Chinese hamster ovary cells. Mol Cell Biol 5:236-241.
17. Elliott EM, Henderson G, Sarangi F, Ling V. 1986. Complete sequence of three α-tubulin cDNAs in Chinese hamster ovary cells: Each encodes a distinct α-tubulin isoprotein. Mol Cell Biol 6:906-913.
18. Fallet-Bianco C, Loeuillet L, Poirier K, Loget P, Chapon F, Pasquier L, Saillour Y, Beldjord C, Chelly J, Francis F. 2008. Neuropathological phenotype of a distinct form of lissencephaly associated with mutations in TUBA1A. Brain 131:2304-2320.
19. Ganguly A, Cabral F. 2011. New insights into mechanisms of resistance to microtubule inhibitors. Biochim Biophys Acta 1816:164-171.
20. Ganguly A, Yang H, Cabral F. 2010. Paclitaxel dependent cell lines reveal a novel drug activity. Mol Cancer Ther 9:2914-2923.
21. Ganguly A, Yang H, Cabral F. 2011. Overexpression of mitotic centromere-associated kinesin stimulates microtubule detachment and confers resistance to paclitaxel. Mol Cancer Ther 10:929-937.
22. Giannakakou P, Sackett DL, Kang Y-K, Zhan Z, Buters JTM, Fojo T, Poruchynsky MS. 1997. Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 272:17118-17125.
23. Giannakakou P, Gussio R, Nogales E, Downing KH, Zaharevitz D, Bollbuck B, Poy G, Sackett D, Nicolaou KC, Fojo T. 2000. A common pharmacophore for epothilone and taxanes: Molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci USA 97:2904-2909.
24. Gonzalez-Garay ML, Chang L, Blade K, Menick DR, Cabral F. 1999. A β-tubulin leucine cluster involved in microtubule assembly and paclitaxel resistance. J Biol Chem 274:23875-23882.
25. Gossen M, Bujard H. 1992. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 89:5547-5551.
26. Hari M, Wang Y, Veeraraghavan S, Cabral F. 2003. Mutations in α- and β-tubulin that stabilize microtubules and confer resistance to colcemid and vinblastine. Mol Cancer Ther 2:597-605.
27. Huzil JT, Chen K, Kurgan L, Tuszynski JA. 2007. The roles of beta-tubulin mutations and isotype expression in acquired drug resistance. Cancer Inform 3:159-181.
28. Janke C, Bulinski JC. 2011. Post-translational regulation of the microtubule cytoskeleton: Mechanisms and functions. Nat Rev Mol Cell Biol 12:773-786.
29. Jansen AC, Oostra A, Desprechins B, De Vlaeminck Y, Verhelst H, Regal L, Verloo P, Bockaert N, Keymolen K, Seneca S, et al. 2011. TUBA1A mutations cause wide spectrum lissencephaly (smooth brain) and suggest that multiple neuronal migration pathways converge on alpha tubulins. Neurology 76:988-992.
30. Jordan MA, Wilson L. 2004. Microtubules as a target for anticancer drugs. Nat Rev 4:253-265.
31. Kanakkanthara A, Wilmes A, O'Brate A, Escuin D, Chan A, Gjyrezi A, Crawford J, Rawson P, Kivell B, Northcote PT, et al. 2011. Peloruside- and laulimalide-resistant human ovarian carcinoma cells have betaI-tubulin mutations and altered expression of betaII- and betaIII-tubulin isotypes. Mol Cancer Ther 10:1419-1429.
32. Keating TJ, Peloquin JG, Rodionov VI, Momcilovic D, Borisy GG. 1997. Microtubule release from the centrosome. Proc Natl Acad Sci USA 94:5078-5083.
33. Kumar RA, Pilz DT, Babatz TD, Cushion TD, Harvey K, Topf M, Yates L, Robb S, Uyanik G, Mancini GMS, et al. 2010. TUBA1A mutations cause wide spectrum lissencephaly (smooth brain) and suggest that multiple neuronal migration pathways converge on alpha tubulins. Hum Mol Gen 19:2817-2827.
34. Kung AL, Sherwood SW, Schimke RT. 1990. Cell line-specific differences in the control of cell cycle progression in the absence of mitosis. Proc Natl Acad Sci USA 87:9553-9557.
35. Lecourtois M, Poirier K, Friocourt G, Jaglin X, Goldenberg A, Saugier-Veber P, Chelly J, Laquerriere A. 2010. Human lissencephaly with cerebellar hypoplasia due to mutations in TUBA1A: Expansion of the foetal neuropathological phenotype. Acta Neuropathol 119:779-789.
36. LeDizet M, Piperno G. 1987. Identification of an acetylation site of Chlamydomonas α-tubulin. Proc Natl Acad Sci USA 84:5720-5724.
37. Li H, DeRosier DJ, Nicholson WV, Nogales E, Downing KH. 2002. Microtubule structure at 8 Å resolution. Structure 10:1317-1328.
38. Loganzo F, Hari M, Annable T, Tan X, Morilla DB, Musto S, Zask A, Kaplan J, Minnick AAJ, May MK, et al. 2004. Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin. Mol Cancer Ther 3:1319-1327.
39. Martello LA, Verdier-Pinard P, Shen H-J, He L, Torres K, Orr GA, Horwitz SB. 2003. Elevated levels of microtubule destabilizing factors in a taxol-resistant/dependent A549 cell line with an α-tubulin mutation. Cancer Res 63:1207-1213.
40. Minotti AM, Barlow SB, Cabral F. 1991. Resistance to antimitotic drugs in Chinese hamster ovary cells correlates with changes in the level of polymerized tubulin. J Biol Chem 266:3987-3994.
41. Mitchison T, Kirschner MW. 1984. Dynamic instability of microtubules. Nature 312:237-242.
42. Morris-Rosendahl DJ, Najm J, Lachmeijer AM, Sztriha L, Martins M, Kuechler A, Haug V, Zeschnigk C, Martin P, Santos M. 2008. Refining the phenotype of alpha-1 α-tubulin (TUB1A) mutation in patients with classical lissencephaly. Clin Genet 74:425-433.
43. Nogales E, Wolf SG, Downing KH. 1998. Structure of the αβ tubulin dimer by electron crystallography. Nature 391:199-203.
44. Nogales E, Whittaker M, Milligan RA, Downing KH. 1999. High-resolution model of the microtubule. Cell 96:79-88.
45. Piperno G, LeDizet M, Chang X. 1987. Microtubules containing acetylated alpha tubulin in mammalian cells in culture. J Cell Biol 104:289-302.
46. Poirier K, Keays DA, Francis F, Saillour Y, Bahi N, Manouvrier S, Fallet-Bianco C, Pasquier L, Toutain A, Tuy FP, et al. 2007. Large spectrum of lissencephaly and pachygyria phenotypes resulting from de novo missense mutations in tubulin alpha 1A (TUBA1A). Hum Mutat 28:1055-1064.
47. Poirier K, Saillour Y, Fourniol F, Francis F, Souville I, Valence S, Desguerre I, Marie Lepage J, Boddaert N, Line Jacquemont M, et al. 2013. Expanding the spectrum of TUBA1A-related cortical dysgenesis to polymicrogyria. Eur J Hum Genet 21:381-385.
48. Poruchynsky MS, Kim JH, Nogales E, Annable T, Loganzo F, Greenberger LM, Sackett DL, Fojo T. 2004. Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability. Biochemistry 43:13944-13954.
49. Schibler M, Cabral F. 1986. Taxol-dependent mutants of Chinese hamster ovary cells with alterations in α- and β-tubulin. J Cell Biol 102:1522-1531.
50. Sheir-Neiss G, Lai MH, Morris NR. 1978. Identification of a gene for β-tubulin in Aspergillus nidulans. Cell 15:639-647.
51. Thomas JH, Neff NF, Botstein D. 1985. Isolation and characterization of mutations in the beta-tubulin gene of Saccharomyces cerevisiae. Genetics 112:715-734.
52. Tischfield MA, Cederquist GY, Gupta MLJ, Engle EC. 2011. Phenotypic spectrum of the tubulin-related disorders and functional implications of disease-causing mutations. Curr Opin Genet Dev 21:286-294.
53. Wang Y, Yin S, Blade K, Cooper G, Menick DR, Cabral F. 2006. Mutations at Leucine 215 of β-tubulin affect paclitaxel sensitivity by two distinct mechanisms. Biochemistry 45:185-194.
54. Westermann S, Weber K. 2003. Post-translational modifications regulate microtubule function. Nat Rev Mol Cell Biol 4:938-947.
55. Yang H, Ganguly A, Cabral F. 2010. Inhibition of cell migration and cell division correlates with distinct effects of microtubule inhibiting drugs. J Biol Chem 285:32242-32250.
56. Yin S, Bhattacharya R, Cabral F. 2010. Human mutations that confer paclitaxel resistance. Mol Cancer Ther 9:327-335.
57. Yin S, Zeng C, Hari M, Cabral F. 2012. Random mutagenesis of β-tubulin defines a set of dispersed mutations that confer paclitaxel resistance. Pharm Res 29:2994-3006.